Large observational studies have found statistical associations between long-term levothyroxine use and modestly higher cancer rates, but no study has established that the drug itself causes cancer. The difficulty is that levothyroxine treats thyroid conditions that may independently alter cancer risk, making it genuinely hard to separate the medication’s effect from the disease it treats. The research picture is also inconsistent: for some cancer types the numbers go up, for others they go down, and for still others there is no difference at all.
What the Population Studies Show
Two large retrospective studies are frequently cited in discussions about levothyroxine and cancer, and their headline numbers sound alarming when taken at face value. A Taiwanese population-based study found that long-term levothyroxine users had roughly a 50 percent higher overall risk of being diagnosed with cancer at any site compared with non-users. The same study flagged elevated risks for brain, skin, pancreatic, and breast cancers specifically.1PubMed Central. Risk of cancer in long-term levothyroxine users: Retrospective population-based study
A Swedish cohort study covering nearly 400,000 cancer cases found a much smaller overall increase: about 6 percent higher risk for men and 8 percent for women taking levothyroxine, after adjusting for other factors. The authors described the excess as “slight” and called for confirmation from other research before drawing conclusions.2Cancer Epidemiology. Levothyroxine treatment is associated with an increased relative risk of overall and organ specific incident cancers – a cohort study of the Swedish population
The gap between a 50 percent elevation in one study and a 6 to 8 percent elevation in another is enormous. Differences in study design, population demographics, follow-up length, and how well each study controlled for other health conditions account for much of that spread. Neither study was a randomized trial, and both relied on medical records rather than controlled experiments. These are important caveats that determine how seriously the raw numbers should be taken.
Why Correlation Is Not Causation Here
The single biggest problem with levothyroxine-cancer research is confounding. People who take levothyroxine have thyroid disease. Thyroid disease itself alters hormone levels, immune function, and metabolism in ways that could independently raise or lower cancer risk. A systematic review and meta-analysis looking at thyroid hormone treatment and breast cancer risk put this plainly: the observational findings “cannot distinguish the effects of thyroid hormone therapy from those of the underlying thyroid disease or residual confounding.”3PubMed Central. Thyroid Hormone Treatment and Breast Cancer Risk in Women: A Systematic Review and Meta-Analysis of Observational Studies
Think of it this way: people who carry umbrellas get rained on more than people who don’t carry umbrellas, but the umbrella doesn’t cause the rain. Levothyroxine is the umbrella. The thyroid disease is the storm. Every study comparing levothyroxine users to non-users is also, unavoidably, comparing people with thyroid problems to people without them. Adjusting for known confounders helps, but thyroid disease influences so many systems that residual confounding is difficult to eliminate entirely.
There is also a surveillance bias issue. People who take levothyroxine see doctors more often. They have more blood work, more imaging, and more routine checkups than the average person who doesn’t take any chronic medication. That extra monitoring makes it more likely that an incidental cancer gets caught, even if levothyroxine played no role in its development.
How Thyroid Hormones Interact With Cancer Cells
Even if the observational data is messy, the biology is not nothing. There is a real molecular mechanism through which thyroid hormones, particularly T4 (the form in levothyroxine), can stimulate cancer cell activity. Tumor cells and rapidly dividing blood vessel cells often express a surface protein called integrin αvβ3. T4 binds to this protein on the outside of the cell and activates growth-promoting signaling pathways inside it.4PubMed. Nongenomic Actions of Thyroid Hormone: The Integrin Component
At this receptor, T4 does several things that favor tumor survival: it promotes cell division, supports the formation of new blood vessels that feed tumors, inhibits a key self-destruct pathway that would otherwise kill damaged cells, and may contribute to resistance against radiation and chemotherapy.5PubMed Central. Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent? In mouse tumor models, animals pushed into a hyperthyroid state showed faster tumor growth and shorter survival, while hypothyroid animals and those given a blocker of this integrin receptor had slower-growing tumors.6PubMed. Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation
This does not mean that levothyroxine at normal replacement doses causes cancer. The animal experiments used hyperthyroid conditions, meaning thyroid hormone levels well above normal. Proper levothyroxine therapy aims to bring hormone levels into the normal range, not above it. Still, the mechanism is worth knowing about, because it explains why researchers take the question seriously and why dose may matter.
Breast Cancer Evidence Goes Both Ways
Breast cancer is probably the most studied organ-specific cancer in relation to levothyroxine, and the results are contradictory enough to be genuinely confusing. A Taiwanese case-control study found that levothyroxine use was associated with about a 24 percent increase in breast cancer risk, with the association stronger in women aged 65 and older.7PubMed. Levothyroxine use and the risk of breast cancer: a nation-wide population-based case-control study
But the Women’s Health Initiative, one of the largest and most carefully designed studies of postmenopausal women’s health ever conducted, found the opposite. Among women with a history of hypothyroidism who took levothyroxine, the risk of invasive breast cancer was about 11 percent lower compared with women who did not take it. The authors described levothyroxine as having “the strongest inverse association with breast cancer risk” among hypothyroidism treatments.8PubMed Central. Breast Cancer Risk in Postmenopausal Women with Medical History of Thyroid Disorder in the Women’s Health Initiative
How can one study show a 24 percent increase and another show an 11 percent decrease? The study populations were different (Taiwanese women spanning all ages versus American postmenopausal women), the comparison groups were structured differently, and the underlying thyroid conditions may have varied. This is exactly the kind of result that signals confounding rather than a clear drug effect. If levothyroxine itself were a strong breast cancer driver, you would not expect to see a protective signal in a large, well-designed cohort.
Colorectal Cancer Tells a Similar Story
Colorectal cancer research adds another layer of contradiction. An Israeli case-control study from the Journal of the National Cancer Institute found that levothyroxine was associated with a roughly 40 percent reduction in colorectal cancer risk, an association that persisted after adjusting for diet, exercise, aspirin use, and family history.9PubMed Central. A case-control study of levothyroxine and the risk of colorectal cancer
A later and larger study from the Netherlands found no association at all. Long-term use of levothyroxine for more than six years showed an adjusted risk essentially equal to one, meaning no difference compared with non-users. Higher cumulative doses also showed no meaningful change.10PubMed Central. Levothyroxine use and the risk of colorectal cancer: a large population-based case–control study
Meanwhile, the Korean dose-response study described below found elevated colorectal cancer risk specifically at the highest levothyroxine doses in thyroid cancer survivors. Three studies, three different answers. The pattern here is not levothyroxine reliably increasing or decreasing colorectal cancer risk; the pattern is that the results depend heavily on the population studied and how the analysis was set up.
Dose Appears to Matter
One of the more interesting findings comes from a Korean cohort study that looked specifically at thyroid cancer survivors and how their subsequent cancer risk varied by levothyroxine dose. The researchers divided patients into four dose groups, from lowest to highest per body weight. At the lowest dose, cancer risk was actually slightly lower than in patients who took no levothyroxine at all. But as doses climbed, so did risk, reaching about 27 percent higher at the highest dose quartile.11Endocrinology and Metabolism. Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine
The dose-response pattern extended to specific cancers. Stomach, colorectal, and liver cancers all showed increased risk at the higher dose tiers, while pancreatic cancer risk was sharply elevated (about two and a half times higher) only at the very highest doses. This gradient is interesting because if levothyroxine were simply a proxy for “having thyroid disease,” you would not necessarily expect a tidy dose-response curve. A dose-dependent pattern is more consistent with a direct biological effect, though it still does not prove one.
There is an important context here: thyroid cancer survivors on high-dose levothyroxine are often taking what is called TSH suppression therapy, where the dose is intentionally set higher than a normal replacement dose to keep thyroid-stimulating hormone low and reduce thyroid cancer recurrence. These patients may effectively be in a mildly hyperthyroid state, which connects back to the integrin αvβ3 mechanism discussed earlier. TSH itself may also play a role, because it can activate signaling pathways that promote cancer cell growth when it binds to TSH receptors on certain cells.12PubMed Central. TSH suppression therapy from an individualized perspective: from mechanism to clinical decision-making Whether overriding TSH with high-dose levothyroxine helps or hurts depends on which signal dominates in a given tissue.
The Thyroidectomy Dilemma
People who have had their thyroid removed for cancer face a particularly tricky version of this question. They have no choice about taking levothyroxine; without a thyroid gland, there is no other way to maintain normal hormone levels. A Korean national cohort study looked at second primary cancers after thyroidectomy for differentiated thyroid cancer and found that both low and high doses of thyroid hormone replacement were linked to a modestly increased risk of developing a new, unrelated cancer. Short-term use (a year or less) and long-term use (over five years) both showed elevated risk.13Scientific Reports. Impact of thyroid hormone replacement on the risk of second cancer after thyroidectomy: a Korean National Cohort Study
The finding that both underdosing and overdosing carried risk suggests that maintaining stable, well-calibrated hormone levels matters more than simply taking less levothyroxine. Endocrinologists already individualize TSH targets for thyroid cancer survivors based on recurrence risk, and these findings reinforce the value of that approach rather than suggesting anyone should stop taking their medication.
Should Pregnant Women Worry About Childhood Cancer?
A separate concern that comes up is whether mothers taking levothyroxine during pregnancy might increase cancer risk in their children. A Danish population-based cohort study specifically examined maternal thyroid diseases and medication use during pregnancy and found no increased risk of childhood cancer in offspring of mothers who used thyroid medications.14PubMed Central. Maternal Thyroid Diseases, Medication Use and Childhood Cancer Risks in Offspring: A Population-Based Cohort Study in Denmark Untreated hypothyroidism during pregnancy carries its own set of risks for the developing baby, so this finding is reassuring for women who need levothyroxine to maintain a healthy pregnancy.
Why Stopping Levothyroxine Is Usually a Bad Idea
Occasionally people read about the cancer association data and wonder whether they should stop taking levothyroxine. For the vast majority of users, this would be a mistake. Untreated hypothyroidism affects cardiovascular health, energy, cognition, cholesterol levels, and many other systems. The theoretical cancer signal from observational studies is small and contested, while the harms of uncontrolled hypothyroidism are well established and substantial.
There is one group for whom deprescribing is being actively studied: older adults who may have been started on levothyroxine for borderline thyroid results and never reassessed. A meta-analysis of existing data found that roughly 37 percent of people who stopped levothyroxine maintained normal thyroid function afterward, though the evidence was low quality and skewed toward middle-aged adults.15PubMed Central. Effects of discontinuation of levothyroxine treatment in older adults: protocol for a self-controlled trial Clinical trials are now underway to see whether community-dwelling adults over 60 can safely withdraw from levothyroxine under medical supervision. But “under medical supervision” is doing a lot of work in that sentence. This is not something to try on your own based on cancer headlines.
What Researchers Still Cannot Untangle
The honest state of the science is that no one knows with confidence whether levothyroxine itself raises cancer risk, whether the underlying thyroid dysfunction is responsible, or whether the whole association is an artifact of how the studies are designed. The biological plausibility exists, because T4 genuinely interacts with cancer-relevant pathways on cell surfaces. The population data is suggestive but inconsistent and plagued by confounding. And there are no randomized controlled trials comparing levothyroxine to placebo for cancer outcomes, because withholding thyroid replacement from people who need it would be unethical.
A few things do seem clearer than others. Dose probably matters, and people on higher-than-necessary doses, especially TSH-suppressive doses, may face higher risk than those on well-calibrated replacement therapy. The specific cancer type matters, too: the data for breast cancer and colorectal cancer are genuinely contradictory, while the signal for pancreatic cancer at high doses and certain gastrointestinal cancers appears more consistent. And the hypothyroidism-cancer relationship itself is complicated; some research using genetic tools has even suggested that hypothyroidism itself may reduce the risk of certain cancers like lung cancer, though this work remains early-stage.16Heliyon. Hypothyroidism reduces the risk of lung cancer through oxidative stress response and the PI3K/Akt signaling pathway
Practical Implications for People Taking Levothyroxine
If you are taking levothyroxine because your doctor determined you need it, the current evidence does not justify stopping or reducing your dose on your own. What it does justify is making sure your dosing is appropriate. Ask your doctor when your TSH was last checked, whether your current dose is still right for your body weight and age, and whether you are on a replacement dose or a suppressive dose. If you are a thyroid cancer survivor on TSH suppression, your endocrinologist should be periodically reassessing whether the benefits of suppression still outweigh the risks, including cancer risk at other sites.
Routine cancer screenings recommended for your age and sex, such as mammography, colonoscopy, and skin checks, remain important regardless of levothyroxine use. There is no special cancer screening protocol recommended specifically for levothyroxine users, but staying current on the standard ones means that if any risk does exist, it is more likely to be caught early. And for the many people who take levothyroxine for autoimmune thyroid disease, keeping inflammation well managed through proper treatment is likely a bigger factor in long-term health than worrying about a contested and modest statistical signal from observational data.